Glaucoma

An international genetic study using multiancestry biobanks has identified novel genetic locations associated with primary open-angle glaucoma, the most common type of glaucoma and the leading cause of irreversible blindness globally. Read More

Researchers at Vanderbilt University Medical Center have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy. Read More

Vanderbilt Eye Institute researchers have discovered that an imbalance in the ionic environment of retinal ganglion cells may contribute to functional impairments in glaucoma. Read More

New findings highlight microRNAs — molecules that regulate gene expression — that are differentially expressed in glaucoma and could be candidate biomarkers or targets for therapy. Read More

A team of researchers, led by David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve vision. Read More

A signaling molecule called interleukin-6 may be a therapeutic target to prevent vision loss or nerve degeneration in glaucoma, Vanderbilt researchers have discovered. Read More

Understanding how the protein TRPV1 helps neurons survive after glaucoma-related stressors could lead to new therapeutic strategies for glaucoma and other neurodegenerative conditions. Read More

Vanderbilt University has launched a regenerative visual neuroscience initiative to develop new ways of treating — and restoring sight to — people who have been blinded by glaucoma, macular degeneration, diabetic retinopathy and eye injuries. Read More

Vanderbilt University Army ROTC senior Cadet Sean Lee was awarded first place for his research and oral presentation on a new to treatment for glaucoma during the Southeastern Medical Scientist Symposium at Emory University School of Medicine in Atlanta, Saturday. Read More

An ion channel protein called TRIPV1 helps retinal neurons survive the elevated eye pressure associated with glaucoma. Read More

Three years ago, a team of researchers led by David Calkins, Ph.D., vice chair and director of Research at the Vanderbilt Eye Institute, showed that the first sign of injury in glaucoma, the leading cause of blindness in the United States, occurs in the brain. Read More

Suzanne Sousan is not afraid of much. Read More

Glaucoma-causing mutations in the gene for myocilin reduce secretion of the protein into the aqueous humor, suggesting a new option for treatment. Read More

Tonia Rex, Ph.D., assistant professor of Ophthalmology and Visual Sciences at the Vanderbilt Eye Institute, was recently named one of 10 winners of the National Institutes of Health competition for ideas on the future of vision research. Read More

Vision experts from around the country recently gathered at the 2012 Vanderbilt Eye Institute symposium “Regenerative Medicine in Glaucoma” to discuss the impact that regenerative medicine has on neurobiological diseases. Read More

Three Vanderbilt University Medical Center faculty members have been awarded grants from the American Health Assistance Foundation to support their research on glaucoma and macular degeneration — the two leading causes of irreversible blindness in the world. Read More

Research to Prevent Blindness has awarded a grant of $100,000 to Vanderbilt’s Department of Ophthalmology and Visual Sciences to support research into the causes, treatment and prevention of blinding diseases. Read More

Researchers have identified a new candidate gene for the most common form of glaucoma, which runs in families. The findings offer novel insights into glaucoma pathology and could lead to targeted treatment strategies. Read More